Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Salmedix Inc

Request full access

Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers

San Diego, United StatesFounded 2000Biotech & Life Sciences

About Salmedix Inc

Salmedix Inc. operated as a clinical-stage oncology drug development company with a strategic focus on hematologic malignancies, or blood cancers. Incorporated in Delaware in November 2000, the firm was co-founded by David S. Kabakoff, Ph.D., who also served as Chairman, CEO, and President, and Dennis A. Carson, M.D., a director at The Rebecca and John Moores UCSD Cancer Center. Dr. Kabakoff brought senior executive experience from pharmaceutical and biotechnology companies like Dura Pharmaceuticals and Corvas International, while Dr. Carson had previously co-founded several other biopharmaceutical firms. The company's business model centered on in-licensing and developing cancer drugs that already had prior human clinical data, a strategy designed to shorten the development pathway and reduce costs.

The company's product pipeline included three clinical-stage candidates: SDX-101, SDX-102, and its lead product, SDX-105. SDX-105, an intravenously administered small molecule, was acquired through an exclusive rights agreement with Fujisawa Deutschland GmbH for development and marketing in the U.S. and Canada. Building on extensive clinical use in Germany, Salmedix advanced SDX-105 into Phase II trials for treating blood cancers like non-Hodgkin's lymphoma and chronic lymphocytic leukemia. SDX-101 was noted for its ability to enhance the activity of traditional chemotherapies, and SDX-102 was a small molecule developed for tumors unable to produce a specific metabolic enzyme. The company's primary market was hematology/oncology.

Salmedix successfully raised significant capital to fund its clinical trials and operations, securing a total of $82.6M through various funding rounds with investors including Aberdare Ventures, Alexandria Venture Investments, and H.I.G. Capital. In June 2005, Salmedix was acquired by Cephalon, Inc. for $160 million. Following the acquisition, the lead product SDX-105 was commercialized by Cephalon under the name Treanda® and became a major success.

Source: Dealroom company data

Salmedix Inc in the San Diego ecosystem

Live from Dealroom

The Salmedix Inc office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

16 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A10 investors entered at this stage

  • InterWest Partners
  • Alexandria Equities
  • Versant Ventures
  • Delphi Ventures
  • CMEA Ventures
  • Aberdare Ventures
  • Alexandria Venture Investments
  • ProQuest Investments
  • Biofrontier Partners
  • GeneChem

Series B and later6 investors entered at this stage

  • HIG Capital
  • Novo Ventures
  • Cariden Technologies
  • Covera Ventures
  • OrbiMed
  • Quilvest Private Equity
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · San Diego HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Salmedix Inc on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Salmedix Inc on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.